

Marcos Gonzalez Daz

List of Publications by Citations

Source: <https://exaly.com/author-pdf/783388/marcos-gonzalez-diaz-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

229
papers

16,896
citations

57
h-index

127
g-index

233
ext. papers

19,096
ext. citations

5.8
avg, IF

5.15
L-index

#	Paper	IF	Citations
229	Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. <i>Leukemia</i> , 2003 , 17, 2257-317	10.7	2404
228	International network of cancer genome projects. <i>Nature</i> , 2010 , 464, 993-8	50.4	1613
227	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , 2011 , 475, 101-5	50.4	1206
226	Standardization and quality control studies of real-time quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. <i>Leukemia</i> , 2003 , 17, 2318-57	10.7	1188
225	Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2011 , 44, 47-52	36.3	752
224	Non-coding recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , 2015 , 526, 519-24	50.4	565
223	Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. <i>Blood</i> , 2004 , 103, 1237-43 ²	2.2	338
222	Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. <i>Blood</i> , 2014 , 123, 3073-9	2.2	306
221	Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. <i>Leukemia</i> , 2017 , 31, 2094-2103	10.7	298
220	Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. <i>Blood</i> , 2001 , 98, 1746-51	2.2	271
219	Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. <i>Blood</i> , 2008 , 111, 3395-402	2.2	258
218	Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. <i>Blood</i> , 2009 , 113, 775-83	2.2	232
217	Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. <i>Annals of Oncology</i> , 1998 , 9, 849-55	10.3	227
216	Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. <i>Blood</i> , 2016 , 127, 2122-30	2.2	188
215	Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. <i>Blood</i> , 2008 , 112, 2709-12	2.2	184
214	MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. <i>Leukemia</i> , 2013 , 27, 1722-8	10.7	179
213	Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. <i>Leukemia</i> , 2010 , 24, 629-37	10.7	173

212	Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. <i>Blood</i> , 2009 , 114, 33-7	2.2	164
211	Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. <i>Haematologica</i> , 2010 , 95, 87-95	6.6	136
210	NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. <i>Leukemia</i> , 2013 , 27, 1100-6	10.7	135
209	Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. <i>Leukemia</i> , 2014 , 28, 391-7	10.7	129
208	Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. <i>Blood</i> , 2008 , 112, 3130-4	2.2	129
207	Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. <i>Blood</i> , 2007 , 110, 3112-21	2.2	123
206	Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. <i>Haematologica</i> , 2005 , 90, 1365-72	6.6	122
205	Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4578-84	2.2	111
204	Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7632-40	2.2	111
203	Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. <i>Leukemia</i> , 2007 , 21, 446-52	10.7	110
202	Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. <i>Blood</i> , 2003 , 101, 4042-6	2.2	109
201	Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. <i>Clinical Cancer Research</i> , 2008 , 14, 155-61	12.9	103
200	Surface marker analysis in acute myeloid leukaemia and correlation with FAB classification. <i>British Journal of Haematology</i> , 1986 , 64, 547-60	4.5	99
199	Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. <i>Blood</i> , 2011 , 117, 1799-805	2.2	95
198	Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. <i>Leukemia</i> , 2002 , 16, 1423-31	10.7	94
197	A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. <i>Leukemia</i> , 2015 , 29, 598-605	10.7	92
196	Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. <i>Blood</i> , 2007 , 109, 4258-63	2.2	90
195	TCRalpha/beta+/CD4+ large granular lymphocytosis: a new clonal T-cell lymphoproliferative disorder. <i>American Journal of Pathology</i> , 2003 , 163, 763-71	5.8	87

194	Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expression. <i>Leukemia</i> , 2001 , 15, 406-14	10.7	84
193	Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. <i>Blood</i> , 2003 , 102, 2994-3002	2.2	83
192	Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. <i>Blood</i> , 2014 , 123, 3790-6	2.2	82
191	SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. <i>Leukemia</i> , 2012 , 26, 2521-9	10.7	81
190	Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. <i>Haematologica</i> , 2009 , 94, 1242-9	6.6	78
189	Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients. <i>Haematologica</i> , 2012 , 97, 1218-24	6.6	74
188	Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. <i>Haematologica</i> , 2010 , 95, 424-31	6.6	72
187	Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. <i>Leukemia</i> , 2005 , 19, 402-9	10.7	72
186	Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. <i>British Journal of Haematology</i> , 2008 , 142, 529-37	4.5	69
185	CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors. <i>Blood</i> , 2007 , 110, 461-7	2.2	69
184	Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2009 , 114, 148-52	2.2	68
183	Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. <i>British Journal of Haematology</i> , 2002 , 118, 1034-40	4.5	68
182	Characterization of aberrant phenotypes in acute myeloblastic leukemia. <i>Annals of Hematology</i> , 1995 , 70, 189-94	3	68
181	Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Castelano-Leon ³ (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. <i>British Journal of Haematology</i> , 1995 , 90, 106-12	4.5	68
180	The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation. <i>Leukemia</i> , 2012 , 26, 1821-8	10.7	67
179	TCRgammadelta+ large granular lymphocyte leukemias reflect the spectrum of normal antigen-selected TCRgammadelta+ T-cells. <i>Leukemia</i> , 2006 , 20, 505-13	10.7	66
178	Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. <i>British Journal of Haematology</i> , 2007 , 136, 590-6	4.5	63
177	Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. <i>British Journal of Haematology</i> , 1996 , 93, 81-8	4.5	62

176	A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. <i>Cytometry</i> , 1994 , 17, 332-9		61
175	Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibling donor transplantation. <i>British Journal of Haematology</i> , 2001 , 114, 931-6	4.5	60
174	Monoclonal TCR-Vbeta13.1+/CD4+/NKa+/CD8-/dim T-LGL lymphocytosis: evidence for an antigen-driven chronic T-cell stimulation origin. <i>Blood</i> , 2007 , 109, 4890-8	2.2	59
173	Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 10534-9	11.5	58
172	Lymphoid subsets and prognostic factors in multiple myeloma. Cooperative Group for the Study of Monoclonal Gammopathies. <i>British Journal of Haematology</i> , 1992 , 80, 305-9	4.5	57
171	Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients. <i>PLoS ONE</i> , 2016 , 11, e0146722	3.7	56
170	CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival. <i>Journal of Pathology</i> , 2015 , 235, 445-55	9.4	55
169	Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease. <i>Cancer Genetics</i> , 2013 , 206, 49-62	2.3	51
168	A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia. <i>Haematologica</i> , 2009 , 94, 364-71	6.6	50
167	Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. <i>Haematologica</i> , 2011 , 96, 1470-7	6.6	48
166	Expanded cells in monoclonal TCR-alpha-beta+/CD4+/NKa+/CD8-/dim T-LGL lymphocytosis recognize hCMV antigens. <i>Blood</i> , 2008 , 112, 4609-16	2.2	48
165	Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. <i>Haematologica</i> , 2007 , 92, 635-42	6.6	48
164	Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. <i>Blood</i> , 2013 , 122, 3951-9	2.2	47
163	Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. <i>British Journal of Haematology</i> , 2002 , 118, 239-42	4.5	47
162	Immunophenotype and DNA cell content in multiple myeloma. <i>Best Practice and Research: Clinical Haematology</i> , 1995 , 8, 735-59		47
161	Prognostic factors and classification in multiple myeloma. <i>British Journal of Cancer</i> , 1989 , 59, 113-8	8.7	46
160	Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia. <i>Leukemia</i> , 2012 , 26, 2360-6	10.7	45
159	High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics. <i>Leukemia Research</i> , 2009 , 33, 1706-9	2.7	44

158	Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA group. <i>British Journal of Haematology</i> , 2001 , 114, 99-103	4.5	44
157	Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. <i>Leukemia</i> , 2001 , 15, 840-5	10.7	43
156	Long FLT3 internal tandem duplications and reduced PML-RAR expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients. <i>Haematologica</i> , 2010 , 95, 745-51	6.6	42
155	Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. <i>Haematologica</i> , 2010 , 95, 1317-24	6.6	41
154	Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies. <i>Leukemia</i> , 2007 , 21, 1413-22	10.7	39
153	Immunological phenotype of neoplasms involving the B cell in the last step of differentiation. <i>British Journal of Haematology</i> , 1986 , 62, 75-83	4.5	39
152	Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results. <i>British Journal of Haematology</i> , 2012 , 157, 67-74	4.5	36
151	Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease--a study within the Europe Against Cancer Program. <i>Leukemia</i> , 2004 , 18, 884-6	10.7	36
150	Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease. <i>British Journal of Cancer</i> , 1993 , 68, 1227-31	8.7	36
149	Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. <i>Blood</i> , 2019 , 134, 2218-2222	2.2	35
148	Design and application of a 23-gene panel by next-generation sequencing for inherited coagulation bleeding disorders. <i>Haemophilia</i> , 2016 , 22, 590-7	3.3	34
147	BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). <i>Annals of Hematology</i> , 2010 , 89, 453-8	3	33
146	The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. <i>Haematologica</i> , 2008 , 93, 1797-805	6.6	33
145	Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics. <i>Nature Communications</i> , 2016 , 7, 11889	17.4	32
144	Incomplete DJH rearrangements of the IgH gene are frequent in multiple myeloma patients: immunobiological characteristics and clinical implications. <i>Leukemia</i> , 2003 , 17, 1398-403	10.7	31
143	Immunophenotypic, genomic and clinical characteristics of blast crisis of chronic myelogenous leukaemia. <i>British Journal of Haematology</i> , 1991 , 79, 408-14	4.5	31
142	Lymphoid subsets in acute myeloid leukemias: increased number of cells with NK phenotype and normal T-cell distribution. <i>Annals of Hematology</i> , 1993 , 67, 217-22	3	31
141	Molecular characterization of chronic lymphocytic leukemia patients with a high number of losses in 13q14. <i>PLoS ONE</i> , 2012 , 7, e48485	3.7	29

140	Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas. <i>Cancer</i> , 2009 , 115, 3728-37	6.4	29
139	Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. <i>Blood</i> , 2010 , 116, 5650-9	2.2	29
138	FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor. <i>The Hematology Journal</i> , 2004 , 5, 239-46		29
137	Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 83	22.4	28
136	Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. <i>Haematologica</i> , 2011 , 96, 468-71	6.6	28
135	Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019 , 104, 576-586	6.6	28
134	Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption. <i>Haematologica</i> , 2014 , 99, e231-4	6.6	27
133	Application of a molecular diagnostic algorithm for haemophilia A and B using next-generation sequencing of entire F8, F9 and VWF genes. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 66-74	7	27
132	Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia. <i>Leukemia Research</i> , 2016 , 40, 1-9	2.7	25
131	Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements. <i>Leukemia</i> , 2007 , 21, 1481-7	10.7	25
130	Common infectious agents and monoclonal B-cell lymphocytosis: a cross-sectional epidemiological study among healthy adults. <i>PLoS ONE</i> , 2012 , 7, e52808	3.7	25
129	p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies. <i>The Hematology Journal</i> , 2001 , 2, 146-9		25
128	Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype. <i>American Journal of Pathology</i> , 2012 , 181, 1879-88	5.8	24
127	Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR. <i>Leukemia</i> , 2003 , 17, 1051-7	10.7	24
126	Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study. <i>Haematologica</i> , 2015 , 100, 1294-300	6.6	23
125	A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2015 , 10, e0143073	3.7	23
124	Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance. <i>Haematologica</i> , 2014 , 99, 155-62	6.6	23
123	Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2006 , 135, 43-51	4.5	23

122	B-cell chronic lymphocytic leukaemia: prognostic value of the immunophenotype and the clinico-haematological features. <i>American Journal of Hematology</i> , 1989 , 31, 26-31	7.1	23
121	Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations. <i>Oncotarget</i> , 2016 , 7, 80916-80924	3.3	23
120	Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2014 , 22, 768-73	1.9	22
119	Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma. <i>British Journal of Haematology</i> , 2008 , 141, 212-5	4.5	22
118	Methylenetetrahydrofolate reductase genotype does not play a role in multiple myeloma pathogenesis. <i>British Journal of Haematology</i> , 2002 , 117, 890-2	4.5	22
117	Hla-DPB1 mismatch in HLA-A-B-DRB1 identical sibling donor stem cell transplantation and acute graft-versus-host disease. <i>Transplantation</i> , 2004 , 77, 1107-10	1.8	22
116	Clinical, biological, and immunophenotypical characteristics of B-cell chronic lymphocytic leukemia with trisomy 12 by fluorescence in situ hybridization. <i>Cytometry</i> , 1995 , 22, 217-22		22
115	T-cell subpopulations in patients with monoclonal gammopathies: essential monoclonal gammopathy, multiple myeloma, and Waldenstrom macroglobulinemia. <i>American Journal of Hematology</i> , 1985 , 20, 267-73	7.1	22
114	Combined patterns of IGHV repertoire and cytogenetic/molecular alterations in monoclonal B lymphocytosis versus chronic lymphocytic leukemia. <i>PLoS ONE</i> , 2013 , 8, e67751	3.7	21
113	A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2016 , 34, 84-92	1.3	21
112	Mapping of genetic abnormalities of primary tumours from metastatic CRC by high-resolution SNP arrays. <i>PLoS ONE</i> , 2010 , 5, e13752	3.7	20
111	Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. <i>Blood Cancer Journal</i> , 2020 , 10, 108	7	20
110	A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms. <i>Blood Advances</i> , 2018 , 2, 1719-1737	7.8	20
109	Low-count monoclonal B-cell lymphocytosis persists after seven years of follow up and is associated with a poorer outcome. <i>Haematologica</i> , 2018 , 103, 1198-1208	6.6	19
108	Gene rearrangement in acute non-lymphoblastic leukaemia: correlation with morphological and immunophenotypic characteristics of blast cells. <i>British Journal of Haematology</i> , 1995 , 89, 104-9	4.5	19
107	Molecular characteristics and gene segment usage in IGH gene rearrangements in multiple myeloma. <i>Haematologica</i> , 2005 , 90, 906-13	6.6	19
106	Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2015 , 54, 668-80	5	18
105	Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group. <i>Annals of Hematology</i> , 2013 , 92, 1151-79	3	18

104	HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. <i>Blood</i> , 2013 , 122, 1448-54	2.2	18
103	Two new 3? PML Breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia 2000 , 27, 35-43		18
102	Molecular and cytogenetic characterization of expanded B-cell clones from multiclonal versus monoclonal B-cell chronic lymphoproliferative disorders. <i>Haematologica</i> , 2014 , 99, 897-907	6.6	17
101	Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients. <i>Blood</i> , 2008 , 111, 5130-41	2.2	17
100	Immunoglobulin lambda isotype gene rearrangements in B cell malignancies. <i>Leukemia</i> , 2001 , 15, 121-7	10.7	17
99	Allogeneic peripheral stem cell transplantation in a case of hereditary sideroblastic anaemia. <i>British Journal of Haematology</i> , 2000 , 109, 658-60	4.5	17
98	Long-term treatment results for acute megakaryoblastic leukaemia patients: a multicentre study. <i>British Journal of Haematology</i> , 1992 , 82, 671-5	4.5	17
97	Combination of interferon and dexamethasone in refractory multiple myeloma. <i>Hematological Oncology</i> , 1990 , 8, 185-9	1.3	17
96	The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma. <i>Annals of Hematology</i> , 2013 , 92, 97-100	3	16
95	The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1144-1152	1.9	16
94	Discrepancies between morphologic, cytochemical, and immunologic characteristics in acute myeloblastic leukemia. <i>American Journal of Clinical Pathology</i> , 1987 , 88, 38-42	1.9	16
93	Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia. <i>Journal of Pathology</i> , 2018 , 245, 61-73	9.4	15
92	CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia. <i>Haematologica</i> , 2015 , 100, e183-5	6.6	15
91	Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. <i>British Journal of Haematology</i> , 2019 , 185, 480-491	4.5	14
90	The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution. <i>Leukemia</i> , 2015 , 29, 1435-7	10.7	14
89	High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2016 , 95, 253-62	3	14
88	Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC). <i>Leukemia and Lymphoma</i> , 2014 , 55, 1007-12	1.9	14
87	Frequency of HLA-A, -B and -DRB1 specificities and haplotypic associations in the population of Castilla y Leń (northwest-central Spain). <i>Tissue Antigens</i> , 2011 , 78, 249-55		13

86	Clinical and immunological findings in large B-cell chronic lymphocytic leukemia. <i>Clinical Immunology and Immunopathology</i> , 1988 , 46, 177-85		13
85	Incidence and Risk Factors for Thrombosis in Patients with Acute Promyelocytic Leukemia. Experience of the PETHEMA LPA96 and LPA99 Protocols.. <i>Blood</i> , 2006 , 108, 1503-1503	2.2	13
84	MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL. <i>BMC Cancer</i> , 2015 , 15, 238	4.8	12
83	Identification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression profiling. <i>Annals of Oncology</i> , 2012 , 23, 2138-2146	10.3	12
82	Functional class switch recombination may occur <i>On vivo</i> On Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2007 , 136, 114-6	4.5	12
81	Thalidomide in combination with cyclophosphamide and dexamethasone (thacydex) is effective in soft-tissue plasmacytomas. <i>British Journal of Haematology</i> , 2002 , 119, 883-4	4.5	12
80	TdT activity in acute myeloid leukemias defined by monoclonal antibodies. <i>American Journal of Hematology</i> , 1986 , 23, 9-17	7.1	12
79	Multipronged functional proteomics approaches for global identification of altered cell signalling pathways in B-cell chronic lymphocytic leukaemia. <i>Proteomics</i> , 2016 , 16, 1193-203	4.8	12
78	TET2 overexpression in chronic lymphocytic leukemia is unrelated to the presence of TET2 variations. <i>BioMed Research International</i> , 2014 , 2014, 814294	3	11
77	Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin. <i>Laboratory Investigation</i> , 2008 , 88, 306-17	5.9	11
76	Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2001 , 28, 665-72	4.4	11
75	Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2020 , 135, 2375-2387	2.2	11
74	Do endothelial cells belong to the primitive stem leukemic clone in CML? Role of extracellular vesicles. <i>Leukemia Research</i> , 2015 , 39, 921-4	2.7	10
73	Immunoblastic lymphoma and associated non-lymphoid malignancies following two cases of Waldenström macroglobulinemia. A review of the literature. <i>European Journal of Haematology</i> , 1993 , 50, 299-301	3.8	10
72	Molecular and epidemiologic findings of childhood acute leukemia in Costa Rica. <i>Journal of Pediatric Hematology/Oncology</i> , 2009 , 31, 131-5	1.2	9
71	Mesenchymal stromal cells (MSC) from JAK2+ myeloproliferative neoplasms differ from normal MSC and contribute to the maintenance of neoplastic hematopoiesis. <i>PLoS ONE</i> , 2017 , 12, e0182470	3.7	9
70	Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. <i>Blood</i> , 2021 , 138, 1830-1842	2.2	9
69	Origin of Waldenström macroglobulinaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2016 , 29, 136-147	4.2	9

68	The association of increased p14ARF/p16INK4a and p15INK4a gene expression with proliferative activity and the clinical course of multiple myeloma. <i>Haematologica</i> , 2006 , 91, 1551-4	6.6	9
67	Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy. <i>Modern Pathology</i> , 2018 , 31, 1318-1331	9.8	8
66	Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia. <i>Leukemia</i> , 2018 , 32, 2701-2705	10.7	8
65	Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Leukemia Research</i> , 2014 , 38, 551-6	2.7	8
64	Pediatric primary follicular mucinosis: further evidence of its relationship with mycosis fungoides. <i>Pediatric Dermatology</i> , 2013 , 30, e218-20	1.9	8
63	The Genotype of the Donor for the (GT) _n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation. <i>PLoS ONE</i> , 2015 , 10, e0140454	3.7	8
62	Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas. <i>Annals of Hematology</i> , 1997 , 74, 79-82	3	8
61	Molecular characterization of complete and incomplete immunoglobulin heavy chain gene rearrangements in hairy cell leukemia. <i>Clinical Lymphoma and Myeloma</i> , 2007 , 7, 573-9		8
60	Acute lymphoid leukemias following either a previous chronic myelogenous leukemia or myelodysplastic syndrome: phenotypic and genomic differences. <i>American Journal of Hematology</i> , 1993 , 43, 256-8	7.1	8
59	Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. <i>Blood Advances</i> , 2021 ,	7.8	8
58	Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. <i>Leukemia</i> , 2021 , 35, 2358-2370	10.7	8
57	Host virus and pneumococcus-specific immune responses in high-count monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia: implications for disease progression. <i>Haematologica</i> , 2017 , 102, 1238-1246	6.6	7
56	Extranodal and nodal diffuse large B cell lymphoma of the head and neck: two different entities?. <i>Annals of Hematology</i> , 2015 , 94, 609-16	3	7
55	Lineage-specific function of Engrailed-2 in the progression of chronic myelogenous leukemia to T-cell blast crisis. <i>Cell Cycle</i> , 2014 , 13, 1717-26	4.7	7
54	Multiple cranial neuropathy and intracranial hypertension associated with all-trans retinoic acid treatment in a young adult patient with acute promyelocytic leukemia. <i>International Journal of Hematology</i> , 2012 , 96, 383-5	2.3	7
53	The value of the immunological subtypes and individual markers compared to classical parameters in the prognosis of acute lymphoblastic leukemia. <i>Hematological Oncology</i> , 1991 , 9, 33-42	1.3	7
52	Quantitative assessment of PML-RAR α and BCR-ABL by two real-time PCR instruments: multiinstitutional laboratory trial. <i>Clinical Chemistry</i> , 2004 , 50, 1088-92	5.5	7
51	Immunological features of sporadic multinodular goiter. <i>The Clinical Investigator</i> , 1993 , 71, 552-8		7

50	MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion. <i>Leukemia Research</i> , 2016 , 46, 30-6	2.7	7
49	Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients. <i>British Journal of Haematology</i> , 2020 , 189, 718-730	4.5	6
48	Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 633-642	1.9	6
47	Helper/suppressor T-cell subpopulations in benign paraproteinaemia. <i>British Journal of Haematology</i> , 1983 , 54, 318-20	4.5	6
46	Subjects with chronic lymphocytic leukaemia-like B-cell clones with stereotyped B-cell receptors frequently show MDS-associated phenotypes on myeloid cells. <i>British Journal of Haematology</i> , 2015 , 168, 258-67	4.5	5
45	Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma. <i>British Journal of Haematology</i> , 2013 , 163, 223-34	4.5	5
44	Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1283-9	1.9	5
43	Status of methylation of p16 gene in multiple myeloma: a comparative study of three methods for its detection. <i>Clinical Biochemistry</i> , 2000 , 33, 415-8	3.5	5
42	Additional Chromosome Abnormalities Have No Prognostic Value in Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Anthracycline-Based Chemotherapy: An Update of the APL96 and APL99 Pethema Protocols.. <i>Blood</i> , 2004 , 104, 2019-2019	2.2	5
41	A novel high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2018 , 9, 26019-26031	3.3	5
40	Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia. <i>Cancers</i> , 2018 , 10,	6.6	5
39	Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas. <i>Blood Cancer Journal</i> , 2019 , 9, 52	7	4
38	Biological Features and Prognostic Impact of Bone Marrow Infiltration in Patients with Diffuse Large B-Cell Lymphoma. <i>Cancers</i> , 2020 , 12,	6.6	4
37	Risk of placenta-mediated pregnancy complications or pregnancy-related VTE in VTE-asymptomatic families of probands with VTE and heterozygosity for factor V Leiden or G20210 prothrombin mutation. <i>European Journal of Haematology</i> , 2012 , 89, 250-5	3.8	4
36	Donor CTLA-4 Genotype Modulates the Immune Response to Minor Histocompatibility Antigen Mismatches. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 2042-2047	4.7	4
35	Molecular and flow cytometry characterization during the follow-up of three simultaneous lymphoproliferative disorders: hairy cell leukemia, monoclonal B-cell lymphocytosis, and CD4(++)/CD8(+/- dim) T-large granular lymphocytosis--a case report. <i>Cytometry Part B - Clinical Cytometry</i> , 2011 , 80, 195-200	3.4	4
34	Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia. <i>Leukemia Research</i> , 2009 , 33, e20-2	2.7	4
33	Clinical and prognostic value of discrepancies in microsatellite DNA regions between recipient and donor in human leukocyte antigen-identical allogeneic transplantation setting. <i>Transplantation</i> , 2008 , 86, 983-90	1.8	4

32	Hyperhomocysteinemia is a risk factor of recurrent coronary event in young patients irrespective to the MTHFR C677T polymorphism. <i>Thrombosis Research</i> , 2007 , 119, 691-8	8.2	4
31	Plasmablastic multiple myeloma: an immunologically different subtype. <i>British Journal of Haematology</i> , 1987 , 66, 275	4.5	4
30	Bone marrow histopathologic patterns and immunologic phenotype in B-cell chronic lymphocytic leukaemia. <i>Blut</i> , 1988 , 57, 19-23		4
29	Coexpression of T- and B-markers in a lymphoproliferative disorder. <i>Scandinavian Journal of Haematology</i> , 1986 , 37, 10-7		3
28	The presence of DRB1*01 allele in multiple myeloma patients is associated with an indolent disease. <i>Tissue Antigens</i> , 2008 , 71, 548-51		3
27	The phenotype of L-CFU and its correlation with the immunological characteristics of the blast cell population in AML. <i>Annals of Hematology</i> , 1994 , 68, 233-6	3	3
26	Interferon and dexamethasone in multiple myeloma patients refractory to chemotherapy. <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27 Suppl 4, S48-9		3
25	T-cell subsets and myeloma cell mass. <i>American Journal of Hematology</i> , 1987 , 25, 235-6	7.1	3
24	Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia.. <i>Molecular Cancer</i> , 2022 , 21, 35	42.1	3
23	Two new 3' PML Breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia 2000 , 27, 35		3
22	Skin involvement in non-secretory myeloma. <i>American Journal of Medicine</i> , 1988 , 84, 373-4	2.4	2
21	Cytochemistry in the differential diagnosis of monoclonal gammopathies. <i>British Journal of Haematology</i> , 1985 , 60, 768-9	4.5	2
20	HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis. <i>PLoS ONE</i> , 2017 , 12, e0172978	3.7	2
19	Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. <i>European Journal of Haematology</i> , 2020 , 104, 162-169	3.8	2
18	The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2318-2326	1.9	2
17	Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia. <i>Medicina Clínica</i> , 2017 , 148, 381.e1-381.e9	1	1
16	Effect of mismatching for mHA UTA2-1 on clinical outcome after HLA-identical sibling donor allo-SCT. <i>Bone Marrow Transplantation</i> , 2015 , 50, 298-300	4.4	1
15	Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis. <i>Hematology Reports</i> , 2014 , 6, 5654	0.9	1

14	Acute leukemia of hybrid phenotype: T lymphoid and myelomonocytic markers. <i>Clinical Immunology and Immunopathology</i> , 1985 , 35, 139-45		1
13	The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients with MDS/AML-Related Somatic Mutations and Inferior Survival. <i>Blood</i> , 2016 , 128, 375-375	2.2	1
12	Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping. <i>British Journal of Haematology</i> , 2021 , 195, 542-551	4.5	1
11	Exportin-1 E571K mutation is a common finding in patients with classical Hodgkin lymphoma. <i>Hematological Oncology</i> , 2019 , 37, 215-218	1.3	1
10	Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative. <i>Annals of Hematology</i> , 2021 , 100, 825-830	3	1
9	MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 5570	6.3	1
8	Sustained complete remission with single agent rituximab in relapsed follicular lymphoma as transformed disease after unrelated reduced intensity conditioning allogeneic stem cell transplantation. <i>Annals of Hematology</i> , 2011 , 90, 227-9	3	0
7	Genetic complexity impacts the clinical outcome of follicular lymphoma patients. <i>Blood Cancer Journal</i> , 2021 , 11, 11	7	0
6	Allele and haplotype frequencies of HLA-A, -B, -C, -DRB1, -DQB1 and -DQA1 in Castile and Leon region from North West of Spain. <i>Human Immunology</i> , 2021 , 82, 549-550	2.3	0
5	Sarcoma histiocítico en intestino delgado: estudio y discusión de un caso con reordenamiento clonal linfocito B. <i>Revista Española De Patología</i> , 2016 , 49, 254-258	1.2	
4	Expression of the FMC7 antigen in cases of B-lymphoproliferative diseases. <i>European Journal of Cancer & Clinical Oncology</i> , 1987 , 23, 1417-9		
3	The Hydropathy Index of the HCDR3 Region of the B-Cell Receptor Identifies Two Subgroups of IGHV-Mutated Chronic Lymphocytic Leukemia Patients With Distinct Outcome. <i>Frontiers in Oncology</i> , 2021 , 11, 723722	5.3	
2	Identification and Characterization of Single Nucleotide Polymorphisms (SNPs) Associated with Genetic Predisposition to Develop Therapy-Related Acute Myeloid Leukemia (t-AML).. <i>Blood</i> , 2004 , 104, 3001-3001	2.2	
1	Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM). <i>PLoS ONE</i> , 2021 , 16, e0257353	3.7	